Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of B-lineage Predominant Lentiviral Vectors for Use in Genetic Therapies for B Cell Disorders

7 Dec 2010

Abstract excerpt

Sustained, targeted, high-level transgene expression in primary B lymphocytes may be useful for gene therapy in B cell disorders. We developed several candidate B-lineage predominant self-inactivating lentiviral vectors (LV) containing alternative enhancer/promoter elements including: the immunoglobulin β (Igβ) (B29) promoter combined with the immunoglobulin µ enhancer (EµB29); and the endogenous BTK promoter...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immunodeficiency and Autoimmune Disorders
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21139568
DOI: 10.1038/mt.2010.259

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of B-lineage Predominant Lentiviral Vectors for Use in Genetic Therapies for B Cell DisordersPMID 21139568Read ↗

An optimized retroviral toolbox for overexpression and genetic perturbation of primary lymphocytesSemantic proximity Read ↗

Sleeping Beauty Transposon‐mediated Engineering of Human Primary T Cells for Therapy of CD19+ Lymphoid MalignanciesSemantic proximity Read ↗

Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospectsSemantic proximity Read ↗

Physiological (TCR-like) regulated lentiviral vectors for the generation of improved CAR-T cellsSemantic proximity Read ↗

Improved Titer and Gene Transfer by Lentiviral Vectors Using Novel, Small β-Globin Locus Control Region ElementsSemantic proximity Read ↗

An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo.Semantic proximity Read ↗

Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndromeSemantic proximity Read ↗

Large-scale discovery of potent, compact and lineage specific enhancers for gene therapy vectorsSemantic proximity Read ↗

Efficient lentiviral transduction of different human and mouse cellsSemantic proximity Read ↗

Evaluation of Mono- and Bi-Functional GLOBE-Based Vectors for Therapy of β-Thalassemia by HBBAS3 Gene Addition and Mutation-Specific RNA Interference.Semantic proximity Read ↗

Development of a bicistronic anti-CD19/CD20 CAR construct including abrogation of unexpected nucleic acid sequence deletionsSemantic proximity Read ↗

Systematic improvements in lentiviral transduction of primary human natural killer cells undergoing ex vivo expansionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.